Bern, Switzerland / Taixing, Jiangsu, China – Space Peptides (Taizhou) Pharmaceutical Co., Ltd. today announced a successful GMP on-site inspection for Written Confirmation, certifying the EU GMP compliance for API manufacture. The successful outcome confirms compliance with EU GMP requirements and enables the company to supply peptide APIs to customers across the European market.
The inspection, conducted from June 3–5, 2026, included a comprehensive review of Space Peptides’ quality management systems, manufacturing operations, facilities, quality control, material management, and validation programs, etc.
The achievement marks a significant milestone in Space Peptides’ international growth strategy and further demonstrates the company’s ability to operate in accordance with globally recognized pharmaceutical quality and compliance standards.
“The successful completion of this on-site inspection serves as a robust validation of our quality system development efforts and has cleared a key compliance hurdle for our entry into the EU market,” said Dr. He Runze, Chairman of Space Peptides. “Taking this breakthrough as a new starting point, we will accelerate the global registration and commercialization of more products and continue to provide customers worldwide with high-quality peptide APIs that meet international standards.”
The successful EU GMP compliance inspection represents an important step in Space Peptides’ ongoing internationalization efforts and reinforces its position as a trusted partner for peptide development and manufacturing. The company has continuously invested in advanced manufacturing capabilities, scientific management systems, and technology innovation to support the growing global demand for peptide therapeutics.
“Achieving Written Confirmation is both a major regulatory milestone and a strong endorsement of the operational excellence that defines Space Peptides,” said Dr. Josef Schröer, Chief Commercial Officer of Space Peptides. “As peptide therapeutics continue to gain momentum worldwide, this accomplishment strengthens our ability to support international pharmaceutical partners with reliable, compliant, and scalable development and manufacturing solutions. We look forward to expanding our global collaborations and bringing innovative peptide medicines to patients faster.”
Looking ahead, Space Peptides will continue to pursue its strategic focus on technology leadership, operational excellence, and regulatory compliance. By aligning its operations with the highest international standards, the company remains committed to delivering high-quality peptide APIs and enabling the next generation of peptide-based therapeutics worldwide.
About Space Peptides:
Headquartered in Switzerland with global operations, Space Peptides provides end-to-end pharmaceutical Peptide CRDMO services—covering discovery, process development, and GMP manufacturing. With a strong commitment to innovation, quality, and sustainability, Space Peptides is shaping the future of peptide therapeutics manufacturing.